Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Authors :: Pin Zhang
Qingyuan Zhang
Zhongsheng Tong
Tao Sun
Wei Li
Quchang Ouyang
Xichun Hu
Ying Cheng
Min Yan
Yueyin Pan
Yuee Teng
Xi Yan
Ying Wang
Weimin Xie
Xiaohua Zeng
Xiaojia Wang
Changlu Hu
Cuizhi Geng
Hongwei Zhang
Wenxin Li
Xinhong Wu
Jincai Zhong
Jingwei Xu
Yanxia Shi
Wenhua Wei
Nayima Bayaxi
Xiaoyu Zhu
Binghe Xu
Source :: The Lancet Oncology. 24:646-657
Publication Year :: 2023
Publisher :: Elsevier BV, 2023.

Tools